Clinical and plasma level characteristics of intramuscular and oral loxapine. Simpson, G.M.; Cooper, T.B.; Lee, J.H. et al.: Psychopharmacology 56: 225 (1978).

A comparison of desipramine and amitriptyline plasma levels and therapeutic response. Proceedings of Annual NCDEU Meeting, 1977. Amin, M.M.; Cooper, R.; Khalid, R. et al.: Psychopharmacology Bulletin 14: 45 (1978).

Haloperidol dose, plasma levels, and clinical response: A double-blind study. Ericksen, S.E.; Hurt, S.W.; Chang, S. et al.: Psychopharmacology Bulletin 14: 15 (1978).

Desipramine plasma levels and therapeutic response. Proceedings of Annual NCDEU Meeting, 1977. Khalid, R.; Amin, M.M. and Ban, T.A.: Psychopharmacology Bulletin 14: 43 (1978).

Plasma levels of neuroleptics vs clinical response. Man, P.L. and Chen, C.H.: Psychosomatics 19: 151 (1978).

Monitoring digoxin therapy. Aronson, J.K.; Grahame-Smith, D.G. and Wigley, F.M.: Quarterly Journal of Medicine 47: 111 (1978).

Heparin concentrations in plasma during surgery in heparin low-dose. Abstract from VIth International Congress on Thrombosis and Haemostasis, 27 June-1 July, 1977. Kruse-Blinkenberg, H.O. and Gormsen, J.: Thrombosis and Haemostasis 38: 272 (1977).

Special considerations with regard to the dosage of tranezamic acid in patients with chronic renal diseases. Andersson, L.; Eriksson, O.; Hedlund, P-O. et al.: Urological Research 6: 83 (1978).

Phenytoin overdose kinetics. Gill, M.A.; Kern, J.W.; Kaneko, J. et al.: Western Journal of Medicine 128: 246 (1978).

The clinical significance of plasma glycoside concentrations in patients with cardiac pacemakers (with 5 figures and 3 tables). Ochs, H.R.; Bodem, G.; Schlehbusch, H. et al.: Zeitschrift fur Kardiologie 67: 109 (1978).

Plasma digoxin levels and the interbeat interval signal in atrial fibrillation (with 2 figures and 4 tables). Penchas, S. and Zajicek, G.: Zeitschrift fur Kardiologie 67: 104 (1978).

Erratum

Tilstone, W.J.; Winchester, J.F. and Reavey, P.C.: The Use of Pharmacokinetic Principles in Determining the Effectiveness of Removal of Toxins from Blood

The following amendments to the article and corrections to table V correct that published originally. We regret the errors which occurred.

Page 25: Section 2, after equation 2 text should read 'first *order* introduction' and not 'first introduction'

Page 26: Legend to figure 2: 'In case (a)' should read 'In case (b)'

Page 27: Equation 8 should read:

$$C_t = \frac{k_o}{V_1 k_{10}} (1 + \ldots$$

and not

$$C_t = \frac{k_a}{V_1 k_{10}} (1 + \ldots$$

Page 29: Between equation 12 and equation 12a, 'various outflow' should read 'venous outflow' and 'Vp' should read '$\hat{V}p$'

Page 32: Table V: The table below replaces that originally published:

Table V. Effect of simulated haemoperfusion on reduction of body levels of pentobarbitone and theophylline

Time	Pentobarbitone		Theophylline	
	N	HP	N	HP
5-10h	5.6	23.2	23.1	34.5
10-15h	5.2	4.3	46.8	51.9
5-15h	10.8	27.5	69.9	86.4

Page 33: Left hand column of text should be altered thus:
Line 4: '2 hours' should read '5 hours'
Line 5: '2 hours' should read '5 hours'
Lines 7 and 8: '...21%...simulation' should read '...414% for pentobarbitone and by 149% for theophylline'
Line 11: '3.8%' should read '347%' and '29.3%' should read '123.6%'

Page 34: Last sentence of last paragraph of section 6 should read 'Data analogous to those of table 1 have been derived for paracetamol using this model (Winchester et al., 1975).'

Page 34: Equation 24 should read:

$$B = \frac{SX_\beta}{k_o(1 - e^{-\beta T})}$$

and not

$$\ldots e^{-\beta t} \ldots$$